All sponsors

MediLink Therapeutics (Suzhou) Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS19
PHASE 3 / 2-37
RECRUITING15
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO17%

Delay Index: of 12 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open MediLink Therapeutics (Suzhou) Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
YL202 for injection; Toripalimab injection
NCT07169994
P1/2RecruitingAdvanced Solid Tumors; Breast Cancer4142026-09-01
YL201 for Injection
NCT06057922
P1/2Active, not recruitingAdvanced Solid Tumor9902026-10
YL202 should be intravenously infused
NCT06107686
P2RecruitingNSCLC; Breast Cancer2002026-11
YL201
NCT07208773
P1/2RecruitingAdvanced Solid Tumors; Non Small Cell Lung Cancer2602027-01
YL202
NCT07202364
P2RecruitingNon Small Cell Lung Cancer; Colorectal Cancer1002027-01-31 (+5 mo)
YL201 for Injection
NCT06241846
P2RecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)1002027-02
YL201
NCT05434234
P1/2RecruitingAdvanced Solid Tumor3122027-04-06 (+33 mo)
YL202 should be intravenously infused
NCT06439771
P2RecruitingLocally Advanced or Metastatic Breast Cancer1802027-07-30 (+12 mo)
intravenous (IV) infusion
NCT06459973
P1/2RecruitingAdvanced Solid Tumors2522027-07-31
YL201
NCT06629597
P3Active, not recruitingNasopharyngeal Carcinoma4002027-12-01
YL201
NCT06612151
P3Active, not recruitingSmall Cell Lung Cancer4382027-12-01
YL202
NCT07461454
P3RecruitingLocally Advanced or Metastatic Breast Cancer3762027-12-31
YL201
NCT07258979
P1/2RecruitingRecurrent or Metastatic Nasopharyngeal Carcinoma2022028-02
YL201
NCT07487896
P3RecruitingAdvanced Esophageal Squamous Cell Carcinoma4402028-04-30
YL202
NCT07416994
P3RecruitingNon-Small Cell Lung Cancer4402028-08-31
YL242
NCT07197827
P1/2RecruitingAdvanced Solid Tumor4242028-09
YL201
NCT07407933
P1/2RecruitingThoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma1182028-11
Tambotatug pelitecan
NCT07803783
P3Not yet recruitingMetastatic Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC)3202029-01
YL201
NCT07739758
P3RecruitingSCLC, Extensive Stage4422029-06